{
  "page_id": 1,
  "metadata": {
    "file_name": "doc_0498.png",
    "image_width": 754,
    "image_height": 1000
  },
  "lines": [
    {
      "text": "Bcl2 Inhibits Apoptosis Associated With Terminal Differentiation of HL-60",
      "bbox": [
        54,
        33,
        677,
        61
      ],
      "confidence": 0.9839871525764465
    },
    {
      "text": "Myeloid Leukemia Cells",
      "bbox": [
        267,
        53,
        471,
        77
      ],
      "confidence": 0.9815258383750916
    },
    {
      "text": "By Louie Naumovski and Michael L. Cleary",
      "bbox": [
        251,
        87,
        488,
        102
      ],
      "confidence": 0.9932527542114258
    },
    {
      "text": "The Bcl2 protein inhibits apoptosis (programmed cell death)",
      "bbox": [
        47,
        114,
        358,
        132
      ],
      "confidence": 0.996597945690155
    },
    {
      "text": "induced by a variety of noxious stimuli. However, relatively",
      "bbox": [
        48,
        127,
        359,
        145
      ],
      "confidence": 0.9822192788124084
    },
    {
      "text": "because of activation of the viral promoter. Differentiation",
      "bbox": [
        379,
        126,
        684,
        141
      ],
      "confidence": 0.9985959529876709
    },
    {
      "text": "not decrease as in normal HL-60 cells but, rather, increased",
      "bbox": [
        380,
        114,
        684,
        127
      ],
      "confidence": 0.9916868805885315
    },
    {
      "text": "little is known about its effect on apoptosis that occurs after",
      "bbox": [
        48,
        142,
        359,
        158
      ],
      "confidence": 0.9900522232055664
    },
    {
      "text": "of the Bcl2-overexpressing cells was similar to that of normal",
      "bbox": [
        379,
        140,
        684,
        155
      ],
      "confidence": 0.9972079992294312
    },
    {
      "text": "terminal differentiation. Bcl2 protein levels decrease during",
      "bbox": [
        48,
        155,
        358,
        172
      ],
      "confidence": 0.9859833121299744
    },
    {
      "text": "HL-60 cells, but they showed little evidence for apoptosis",
      "bbox": [
        380,
        154,
        684,
        167
      ],
      "confidence": 0.9832106232643127
    },
    {
      "text": "differentiation of myeloid cells into granulocytes that subse-",
      "bbox": [
        49,
        168,
        358,
        188
      ],
      "confidence": 0.9822903871536255
    },
    {
      "text": "and had a prolonged survival. These studies show that the",
      "bbox": [
        380,
        169,
        683,
        182
      ],
      "confidence": 0.9818586111068726
    },
    {
      "text": "quently undergo apoptosis, but the potential role of Bcl2 in",
      "bbox": [
        49,
        183,
        359,
        201
      ],
      "confidence": 0.9912266135215759
    },
    {
      "text": "survival-enhancing properties of Bcl2 counteract pro-",
      "bbox": [
        380,
        183,
        684,
        197
      ],
      "confidence": 0.997785747051239
    },
    {
      "text": "coupling survival and differentiation remains undefined. To",
      "bbox": [
        48,
        197,
        358,
        214
      ],
      "confidence": 0.9959152936935425
    },
    {
      "text": "grammed cell death that accompanies terminal differentia-",
      "bbox": [
        379,
        196,
        683,
        211
      ],
      "confidence": 0.9905844330787659
    },
    {
      "text": "ascertain the relationship between decreasing Bcl2 levels",
      "bbox": [
        48,
        210,
        358,
        227
      ],
      "confidence": 0.9974769353866577
    },
    {
      "text": "tion; however, Bcl2 has no significant effect on differentia-",
      "bbox": [
        378,
        209,
        683,
        224
      ],
      "confidence": 0.9962082505226135
    },
    {
      "text": "and the onset of apoptosis in differentiating myeloid cells,",
      "bbox": [
        48,
        224,
        358,
        240
      ],
      "confidence": 0.9741546511650085
    },
    {
      "text": "tion itself, suggesting that apoptosis and differentiation are",
      "bbox": [
        379,
        224,
        683,
        237
      ],
      "confidence": 0.9864450097084045
    },
    {
      "text": "Bcl2 was hyperexpressed in the HL-60 cell line after retroviral",
      "bbox": [
        48,
        237,
        358,
        253
      ],
      "confidence": 0.99667888879776
    },
    {
      "text": "regulated independently in myeloid cells.",
      "bbox": [
        380,
        239,
        593,
        249
      ],
      "confidence": 0.977425754070282
    },
    {
      "text": "gene transfer. After treatment of HL-60/BCL2 cells with all-",
      "bbox": [
        48,
        250,
        357,
        267
      ],
      "confidence": 0.9914747476577759
    },
    {
      "text": "1994 by The American Society of Hematology.",
      "bbox": [
        378,
        249,
        632,
        265
      ],
      "confidence": 0.9909707903862
    },
    {
      "text": "trans retinoic acid or phorbol myristic acid, Bcl2 levels did",
      "bbox": [
        50,
        266,
        358,
        279
      ],
      "confidence": 0.9936625361442566
    },
    {
      "text": "T",
      "bbox": [
        49,
        297,
        77,
        327
      ],
      "confidence": 0.9998272061347961
    },
    {
      "text": "VHE BCL.2 ONCOGENE was initially identified at the",
      "bbox": [
        71,
        296,
        357,
        310
      ],
      "confidence": 0.9635216593742371
    },
    {
      "text": "However, it is unclear whether a decrease in Bcl2 levels may",
      "bbox": [
        379,
        295,
        684,
        309
      ],
      "confidence": 0.9907302260398865
    },
    {
      "text": "breakpoint of the t(14; 18)(q32;q21), the most common",
      "bbox": [
        81,
        312,
        358,
        326
      ],
      "confidence": 0.9611223340034485
    },
    {
      "text": "be required for cells to differentiate or undergo apoptosis.",
      "bbox": [
        378,
        309,
        685,
        325
      ],
      "confidence": 0.9817297458648682
    },
    {
      "text": "chromosomal translocation in human lymphoid malignan-",
      "bbox": [
        47,
        325,
        359,
        343
      ],
      "confidence": 0.9791813492774963
    },
    {
      "text": "To address the potential rolc of Bcl2 in blocking terminal",
      "bbox": [
        392,
        325,
        686,
        339
      ],
      "confidence": 0.9731256365776062
    },
    {
      "text": "cies.1-3 This translocation juxtaposes the Ig heavy chain gene",
      "bbox": [
        48,
        340,
        359,
        358
      ],
      "confidence": 0.9785858392715454
    },
    {
      "text": "differentiation or its attendant programmed cell death, Bcl2",
      "bbox": [
        378,
        339,
        686,
        354
      ],
      "confidence": 0.9849463701248169
    },
    {
      "text": "enhancer with the BCL.2 gene, resulting in constitutive ex-",
      "bbox": [
        48,
        354,
        359,
        373
      ],
      "confidence": 0.9768829345703125
    },
    {
      "text": "was hyperexpressed in HL-60 cells after retroviral gene",
      "bbox": [
        378,
        354,
        686,
        369
      ],
      "confidence": 0.9970019459724426
    },
    {
      "text": "pression of BCL2 transcripts* with subsequent overex-",
      "bbox": [
        48,
        368,
        359,
        388
      ],
      "confidence": 0.9856207370758057
    },
    {
      "text": "agents, Bcl2 protein levels did not decline but, rather. in-",
      "bbox": [
        376,
        381,
        688,
        401
      ],
      "confidence": 0.9739971160888672
    },
    {
      "text": "transfer. When these cells were treated with differentiating",
      "bbox": [
        377,
        369,
        687,
        384
      ],
      "confidence": 0.9743614792823792
    },
    {
      "text": "pression of the 24- to 26-kD Bcl2 protein.° Overexpression",
      "bbox": [
        48,
        383,
        359,
        402
      ],
      "confidence": 0.9777117967605591
    },
    {
      "text": "creased because of the activation of the retroviral promoter.",
      "bbox": [
        376,
        396,
        687,
        415
      ],
      "confidence": 0.9880895018577576
    },
    {
      "text": "of Bcl2 in lymphoid cells in culture68 and in transgenic",
      "bbox": [
        49,
        398,
        358,
        416
      ],
      "confidence": 0.9523922801017761
    },
    {
      "text": "Overexpression of Bcl2 did not prevent differentiation into",
      "bbox": [
        378,
        412,
        687,
        428
      ],
      "confidence": 0.9823828935623169
    },
    {
      "text": "mice®-12 prevents apoptosis (programmed cell death) induced",
      "bbox": [
        48,
        413,
        358,
        431
      ],
      "confidence": 0.9727762937545776
    },
    {
      "text": "by a wide variety of agents, such as steroids, γ irradiation.",
      "bbox": [
        49,
        427,
        358,
        447
      ],
      "confidence": 0.9876258373260498
    },
    {
      "text": "granulocytes or macrophage-like cells, but did extend the life",
      "bbox": [
        377,
        426,
        687,
        445
      ],
      "confidence": 0.997016429901123
    },
    {
      "text": "growth factor deprivation, and other injurious agents. Bcl2",
      "bbox": [
        48,
        441,
        358,
        462
      ],
      "confidence": 0.9826841950416565
    },
    {
      "text": "of differentiated cells by blocking apoptosis. These studies",
      "bbox": [
        377,
        441,
        687,
        458
      ],
      "confidence": 0.9930868744850159
    },
    {
      "text": "also has been implicated in positive selection of thymocytes",
      "bbox": [
        48,
        457,
        358,
        476
      ],
      "confidence": 0.9756458401679993
    },
    {
      "text": "suggest that, although differentiation and apoptosis occur",
      "bbox": [
        377,
        457,
        688,
        473
      ],
      "confidence": 0.9863284826278687
    },
    {
      "text": "concomitantly, they are regulated independently in differ-",
      "bbox": [
        377,
        471,
        687,
        488
      ],
      "confidence": 0.9900758862495422
    },
    {
      "text": "and in maintenance of B-cell memory through its effects",
      "bbox": [
        49,
        473,
        357,
        489
      ],
      "confidence": 0.9787279963493347
    },
    {
      "text": "on survival at specific stages of lymphoid development and",
      "bbox": [
        49,
        486,
        358,
        504
      ],
      "confidence": 0.9824042320251465
    },
    {
      "text": "differentiation.10.1: However, the precise role of Bcl2 in the",
      "bbox": [
        50,
        502,
        357,
        517
      ],
      "confidence": 0.947981059551239
    },
    {
      "text": "entiating myeloid cells.",
      "bbox": [
        378,
        488,
        502,
        501
      ],
      "confidence": 0.9993208050727844
    },
    {
      "text": "coupling of survival and differentiation or in controlling cell",
      "bbox": [
        50,
        517,
        357,
        532
      ],
      "confidence": 0.9763405323028564
    },
    {
      "text": "MATERIALS AND METHODS",
      "bbox": [
        457,
        517,
        611,
        530
      ],
      "confidence": 0.9961596727371216
    },
    {
      "text": "·death that accompanies terminal differentiation remains un-",
      "bbox": [
        48,
        533,
        357,
        546
      ],
      "confidence": 0.9853127002716064
    },
    {
      "text": "defined.",
      "bbox": [
        50,
        547,
        95,
        561
      ],
      "confidence": 0.9475789070129395
    },
    {
      "text": "Reagents. ATRA and PMA were obtained from Sigma Chemical",
      "bbox": [
        388,
        534,
        690,
        549
      ],
      "confidence": 0.9780545234680176
    },
    {
      "text": "A cellular lineage amenable for studying this potential",
      "bbox": [
        64,
        561,
        357,
        575
      ],
      "confidence": 0.988399088382721
    },
    {
      "text": "Co (St Louis, MO). ATRA was dissolved in ethanol at 1 mmol/L",
      "bbox": [
        377,
        548,
        690,
        563
      ],
      "confidence": 0.975221574306488
    },
    {
      "text": "and used at 1 μmol/L. to induce differentiation. PMA was dissolved",
      "bbox": [
        377,
        561,
        691,
        577
      ],
      "confidence": 0.9806981086730957
    },
    {
      "text": "linkage is the myeloid lineage, because differentiation-linked",
      "bbox": [
        50,
        577,
        357,
        590
      ],
      "confidence": 0.9826191067695618
    },
    {
      "text": "in DMSO at 16 μmol/L and used at 16 nmol/L to induce differentia-",
      "bbox": [
        377,
        576,
        690,
        590
      ],
      "confidence": 0.9720738530158997
    },
    {
      "text": "regulation of Bcl2 expression occurs in these cells. Expres-",
      "bbox": [
        48,
        589,
        358,
        607
      ],
      "confidence": 0.9664319753646851
    },
    {
      "text": "tion.",
      "bbox": [
        378,
        592,
        402,
        604
      ],
      "confidence": 0.9996036291122437
    },
    {
      "text": "sion of Bcl2 protein has been shown by immunohistochemis-",
      "bbox": [
        49,
        605,
        357,
        619
      ],
      "confidence": 0.9925594925880432
    },
    {
      "text": "Cell culture. HL-60 cells were grown in RPMI 1640 medium",
      "bbox": [
        390,
        604,
        692,
        617
      ],
      "confidence": 0.9744548797607422
    },
    {
      "text": "try in early myeloid cells in the bone marrow, but decreases",
      "bbox": [
        50,
        620,
        358,
        634
      ],
      "confidence": 0.9898793697357178
    },
    {
      "text": "supplemented with 10% (vol/vol) fetal calf serum and 100 U/mL.",
      "bbox": [
        378,
        615,
        693,
        632
      ],
      "confidence": 0.982856035232544
    },
    {
      "text": "with cell imaturation, becoming almost undetectable in termi-",
      "bbox": [
        49,
        635,
        358,
        648
      ],
      "confidence": 0.9852367043495178
    },
    {
      "text": "penicillin, 290 μg/mL L-glutamine, and 100 μg/mL streptomycin.",
      "bbox": [
        378,
        629,
        692,
        645
      ],
      "confidence": 0.9772607684135437
    },
    {
      "text": "nally differentiated neutrophils,13,* which subsequently un-",
      "bbox": [
        48,
        648,
        358,
        663
      ],
      "confidence": 0.9789222478866577
    },
    {
      "text": "Cells were maintained ut 37°C in a 5% CO-/95% air incubutor.",
      "bbox": [
        378,
        643,
        691,
        657
      ],
      "confidence": 0.9594169855117798
    },
    {
      "text": "dergo programmed cell death.\"5 However, the effects of Bel2",
      "bbox": [
        48,
        663,
        358,
        678
      ],
      "confidence": 0.9704261422157288
    },
    {
      "text": "HL-60 stock cultures infected with: the control neomycin or BCL2",
      "bbox": [
        380,
        657,
        692,
        670
      ],
      "confidence": 0.9869939684867859
    },
    {
      "text": "overexpression in the myeloid lineage have not been well",
      "bbox": [
        48,
        678,
        359,
        694
      ],
      "confidence": 0.9827361702919006
    },
    {
      "text": "retroviruses were grown as above in the presence of 500 ug/mL",
      "bbox": [
        379,
        669,
        692,
        684
      ],
      "confidence": 0.9747665524482727
    },
    {
      "text": "characterized, although Bcl2 has been shown to increase the",
      "bbox": [
        47,
        693,
        358,
        709
      ],
      "confidence": 0.9860549569129944
    },
    {
      "text": "survival of interleukin-3 (IL-3)-dependent FDC-P1 myeloid",
      "bbox": [
        47,
        708,
        358,
        723
      ],
      "confidence": 0.9925031661987305
    },
    {
      "text": "leukemia cells under conditions of IL-3 deprivation.6",
      "bbox": [
        47,
        722,
        326,
        737
      ],
      "confidence": 0.9894848465919495
    },
    {
      "text": "From the Department of Pediutrics. Division of Hematology/On-",
      "bbox": [
        392,
        720,
        691,
        730
      ],
      "confidence": 0.9715568423271179
    },
    {
      "text": "The Bcl2 protein has also been detected in myeloid leuke-",
      "bbox": [
        61,
        737,
        357,
        752
      ],
      "confidence": 0.9820391535758972
    },
    {
      "text": "cology. Lucile Salter Packard Children's Hospital at Stanford; and",
      "bbox": [
        379,
        732,
        693,
        745
      ],
      "confidence": 0.9861416816711426
    },
    {
      "text": "mias and myeloid leukemia cell lines, including the human",
      "bbox": [
        46,
        752,
        358,
        768
      ],
      "confidence": 0.9904573559761047
    },
    {
      "text": "the Department of Pathology, Laboratory of Experimental Oncology.",
      "bbox": [
        379,
        744,
        692,
        759
      ],
      "confidence": 0.989237368106842
    },
    {
      "text": "HL-6O cell line.14 This cell line, which was derived from a",
      "bbox": [
        46,
        767,
        358,
        782
      ],
      "confidence": 0.9732957482337952
    },
    {
      "text": "Stanford University School of Medicine, Stanford, CA.",
      "bbox": [
        380,
        759,
        633,
        772
      ],
      "confidence": 0.9905909299850464
    },
    {
      "text": "Submitted October 13, 1993; accepted December 14, 1993.",
      "bbox": [
        391,
        772,
        669,
        785
      ],
      "confidence": 0.9842680096626282
    },
    {
      "text": "patient with clinical features of promyelocytic leukemia, has",
      "bbox": [
        46,
        781,
        357,
        797
      ],
      "confidence": 0.9864771366119385
    },
    {
      "text": "Supported by National Institutes of Health Grant No. CA42971.",
      "bbox": [
        391,
        786,
        691,
        799
      ],
      "confidence": 0.9776750802993774
    },
    {
      "text": "been extensively characterized with respect to its prolifera-",
      "bbox": [
        45,
        796,
        357,
        813
      ],
      "confidence": 0.9895926713943481
    },
    {
      "text": "LN. is a postdoctoral fellow of the Howard Hughes Medical Insti-",
      "bbox": [
        379,
        798,
        692,
        814
      ],
      "confidence": 0.9882766008377075
    },
    {
      "text": "tion and differentiation properties.16-18 It can be induced to",
      "bbox": [
        45,
        811,
        358,
        828
      ],
      "confidence": 0.9745325446128845
    },
    {
      "text": "tute. M.L.C. is a scholar of the Leakemia Society of America.",
      "bbox": [
        378,
        812,
        667,
        828
      ],
      "confidence": 0.9868671894073486
    },
    {
      "text": "differentiate along the myeloid pathway into granulocytes",
      "bbox": [
        46,
        827,
        357,
        844
      ],
      "confidence": 0.9894957542419434
    },
    {
      "text": "Address reprint requests to Micisael L. Cleary, MD, Department",
      "bbox": [
        389,
        826,
        693,
        842
      ],
      "confidence": 0.9763598442077637
    },
    {
      "text": "with dimethylsulfoxide (DMSO) or all-trans retinoic acid",
      "bbox": [
        45,
        842,
        357,
        858
      ],
      "confidence": 0.9914063215255737
    },
    {
      "text": "of Pathology. Stanford Universit: School of Medicine. 300 Pasteur",
      "bbox": [
        378,
        840,
        692,
        856
      ],
      "confidence": 0.9761258959770203
    },
    {
      "text": "(ATRA). 19-2i After differentiation ·with ATRA, the granulo-",
      "bbox": [
        44,
        855,
        358,
        875
      ],
      "confidence": 0.9716504812240601
    },
    {
      "text": "Dr. Stanford, CA 94305-5324.",
      "bbox": [
        379,
        855,
        521,
        868
      ],
      "confidence": 0.9816164374351501
    },
    {
      "text": "cytes die through apoptosis in a process similar to that seen",
      "bbox": [
        45,
        872,
        357,
        888
      ],
      "confidence": 0.9809682369232178
    },
    {
      "text": "The publication costs of this article were defrayed in part by page",
      "bbox": [
        389,
        867,
        692,
        884
      ],
      "confidence": 0.994585394859314
    },
    {
      "text": "in normal human neutrophils.22 HL-60 cells can also differ-",
      "bbox": [
        46,
        888,
        356,
        901
      ],
      "confidence": 0.9735136032104492
    },
    {
      "text": "charge payment. This article must therefore be hereby marked",
      "bbox": [
        378,
        879,
        692,
        898
      ],
      "confidence": 0.9909259676933289
    },
    {
      "text": "\"advertisement\" in accondance with 18 U.S.C. section 1734 solely to",
      "bbox": [
        378,
        891,
        692,
        914
      ],
      "confidence": 0.9606613516807556
    },
    {
      "text": "entiate into macrophage-like cells when treated with phorbol",
      "bbox": [
        46,
        903,
        357,
        916
      ],
      "confidence": 0.997911810874939
    },
    {
      "text": "indicate this fact.",
      "bbox": [
        376,
        906,
        461,
        923
      ],
      "confidence": 0.9860190153121948
    },
    {
      "text": "myristic acid (PMA).23 Bcl2 levels decrease during differen-",
      "bbox": [
        45,
        916,
        356,
        931
      ],
      "confidence": 0.9700014591217041
    },
    {
      "text": "© 1994 by The American Society of Hematology.",
      "bbox": [
        388,
        919,
        621,
        941
      ],
      "confidence": 0.9751275777816772
    },
    {
      "text": "tiation of HL-60 into neutrophils or macrophage-like cells.\"4",
      "bbox": [
        44,
        929,
        357,
        949
      ],
      "confidence": 0.965693473815918
    },
    {
      "text": "0006-4971/94/8308-0006$3.00/G",
      "bbox": [
        388,
        933,
        542,
        951
      ],
      "confidence": 0.9819884300231934
    },
    {
      "text": "Blcod, Vol 83, No 8 (April 15), 1994: pp 2261-2267",
      "bbox": [
        45,
        963,
        276,
        980
      ],
      "confidence": 0.9755655527114868
    },
    {
      "text": "2261",
      "bbox": [
        667,
        974,
        693,
        989
      ],
      "confidence": 0.9752230644226074
    }
  ],
  "full_text": "Bcl2 Inhibits Apoptosis Associated With Terminal Differentiation of HL-60\nMyeloid Leukemia Cells\nBy Louie Naumovski and Michael L. Cleary\nThe Bcl2 protein inhibits apoptosis (programmed cell death)\ninduced by a variety of noxious stimuli. However, relatively\nbecause of activation of the viral promoter. Differentiation\nnot decrease as in normal HL-60 cells but, rather, increased\nlittle is known about its effect on apoptosis that occurs after\nof the Bcl2-overexpressing cells was similar to that of normal\nterminal differentiation. Bcl2 protein levels decrease during\nHL-60 cells, but they showed little evidence for apoptosis\ndifferentiation of myeloid cells into granulocytes that subse-\nand had a prolonged survival. These studies show that the\nquently undergo apoptosis, but the potential role of Bcl2 in\nsurvival-enhancing properties of Bcl2 counteract pro-\ncoupling survival and differentiation remains undefined. To\ngrammed cell death that accompanies terminal differentia-\nascertain the relationship between decreasing Bcl2 levels\ntion; however, Bcl2 has no significant effect on differentia-\nand the onset of apoptosis in differentiating myeloid cells,\ntion itself, suggesting that apoptosis and differentiation are\nBcl2 was hyperexpressed in the HL-60 cell line after retroviral\nregulated independently in myeloid cells.\ngene transfer. After treatment of HL-60/BCL2 cells with all-\n1994 by The American Society of Hematology.\ntrans retinoic acid or phorbol myristic acid, Bcl2 levels did\nT\nVHE BCL.2 ONCOGENE was initially identified at the\nHowever, it is unclear whether a decrease in Bcl2 levels may\nbreakpoint of the t(14; 18)(q32;q21), the most common\nbe required for cells to differentiate or undergo apoptosis.\nchromosomal translocation in human lymphoid malignan-\nTo address the potential rolc of Bcl2 in blocking terminal\ncies.1-3 This translocation juxtaposes the Ig heavy chain gene\ndifferentiation or its attendant programmed cell death, Bcl2\nenhancer with the BCL.2 gene, resulting in constitutive ex-\nwas hyperexpressed in HL-60 cells after retroviral gene\npression of BCL2 transcripts* with subsequent overex-\nagents, Bcl2 protein levels did not decline but, rather. in-\ntransfer. When these cells were treated with differentiating\npression of the 24- to 26-kD Bcl2 protein.° Overexpression\ncreased because of the activation of the retroviral promoter.\nof Bcl2 in lymphoid cells in culture68 and in transgenic\nOverexpression of Bcl2 did not prevent differentiation into\nmice®-12 prevents apoptosis (programmed cell death) induced\nby a wide variety of agents, such as steroids, γ irradiation.\ngranulocytes or macrophage-like cells, but did extend the life\ngrowth factor deprivation, and other injurious agents. Bcl2\nof differentiated cells by blocking apoptosis. These studies\nalso has been implicated in positive selection of thymocytes\nsuggest that, although differentiation and apoptosis occur\nconcomitantly, they are regulated independently in differ-\nand in maintenance of B-cell memory through its effects\non survival at specific stages of lymphoid development and\ndifferentiation.10.1: However, the precise role of Bcl2 in the\nentiating myeloid cells.\ncoupling of survival and differentiation or in controlling cell\nMATERIALS AND METHODS\n·death that accompanies terminal differentiation remains un-\ndefined.\nReagents. ATRA and PMA were obtained from Sigma Chemical\nA cellular lineage amenable for studying this potential\nCo (St Louis, MO). ATRA was dissolved in ethanol at 1 mmol/L\nand used at 1 μmol/L. to induce differentiation. PMA was dissolved\nlinkage is the myeloid lineage, because differentiation-linked\nin DMSO at 16 μmol/L and used at 16 nmol/L to induce differentia-\nregulation of Bcl2 expression occurs in these cells. Expres-\ntion.\nsion of Bcl2 protein has been shown by immunohistochemis-\nCell culture. HL-60 cells were grown in RPMI 1640 medium\ntry in early myeloid cells in the bone marrow, but decreases\nsupplemented with 10% (vol/vol) fetal calf serum and 100 U/mL.\nwith cell imaturation, becoming almost undetectable in termi-\npenicillin, 290 μg/mL L-glutamine, and 100 μg/mL streptomycin.\nnally differentiated neutrophils,13,* which subsequently un-\nCells were maintained ut 37°C in a 5% CO-/95% air incubutor.\ndergo programmed cell death.\"5 However, the effects of Bel2\nHL-60 stock cultures infected with: the control neomycin or BCL2\noverexpression in the myeloid lineage have not been well\nretroviruses were grown as above in the presence of 500 ug/mL\ncharacterized, although Bcl2 has been shown to increase the\nsurvival of interleukin-3 (IL-3)-dependent FDC-P1 myeloid\nleukemia cells under conditions of IL-3 deprivation.6\nFrom the Department of Pediutrics. Division of Hematology/On-\nThe Bcl2 protein has also been detected in myeloid leuke-\ncology. Lucile Salter Packard Children's Hospital at Stanford; and\nmias and myeloid leukemia cell lines, including the human\nthe Department of Pathology, Laboratory of Experimental Oncology.\nHL-6O cell line.14 This cell line, which was derived from a\nStanford University School of Medicine, Stanford, CA.\nSubmitted October 13, 1993; accepted December 14, 1993.\npatient with clinical features of promyelocytic leukemia, has\nSupported by National Institutes of Health Grant No. CA42971.\nbeen extensively characterized with respect to its prolifera-\nLN. is a postdoctoral fellow of the Howard Hughes Medical Insti-\ntion and differentiation properties.16-18 It can be induced to\ntute. M.L.C. is a scholar of the Leakemia Society of America.\ndifferentiate along the myeloid pathway into granulocytes\nAddress reprint requests to Micisael L. Cleary, MD, Department\nwith dimethylsulfoxide (DMSO) or all-trans retinoic acid\nof Pathology. Stanford Universit: School of Medicine. 300 Pasteur\n(ATRA). 19-2i After differentiation ·with ATRA, the granulo-\nDr. Stanford, CA 94305-5324.\ncytes die through apoptosis in a process similar to that seen\nThe publication costs of this article were defrayed in part by page\nin normal human neutrophils.22 HL-60 cells can also differ-\ncharge payment. This article must therefore be hereby marked\n\"advertisement\" in accondance with 18 U.S.C. section 1734 solely to\nentiate into macrophage-like cells when treated with phorbol\nindicate this fact.\nmyristic acid (PMA).23 Bcl2 levels decrease during differen-\n© 1994 by The American Society of Hematology.\ntiation of HL-60 into neutrophils or macrophage-like cells.\"4\n0006-4971/94/8308-0006$3.00/G\nBlcod, Vol 83, No 8 (April 15), 1994: pp 2261-2267\n2261"
}